VESICARE Rx

Indications for VESICARE:

Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Adult Dose for VESICARE:

Swallow whole with water. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl<30mL/min), moderate hepatic impairment, or concomitant potent CYP3A4 inhibitors (eg, ketoconazole): max 5mg once daily.

Children's Dose for VESICARE:

Not established.

Pharmacological Class:

Antispasmodic/anticholinergic.

Contraindications:

GI or urinary retention. Uncontrolled narrow-angle glaucoma.

Warnings/Precautions:

Severe hepatic impairment: not recommended. Bladder outflow obstruction. GI obstructive disorders. Decreased GI motility. Controlled narrow-angle glaucoma. History of QT prolongation. Renal or hepatic insufficiency. Monitor for signs of CNS effects esp. after initiating treatment or dose increases; consider dose reduction or discontinue if occurs. Exposure to high environmental temperature. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics. Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole). May be antagonized by CYP3A4 inducers.

Adverse Reactions:

Anticholinergic effects (eg, dry mouth, constipation, blurred vision), urinary tract infection, nausea, dyspepsia; CNS effects (eg, headache, confusion, somnolence), angioedema (discontinue if occurs); rare: anaphylactic reactions.

Metabolism:

Hepatic (CYP3A4). 98% protein bound.

Elimination:

Renal (major), fecal (minor).

Generic Availability:

NO

How Supplied:

Tabs—30, 90